1. Introduction {#sec1-1}
===============

Bipolar disorder and schizophrenia are relatively common psychiatric disorders that are predicted to affect approximately 1--2% and 1% of the population, respectively ^\[[@ref1],[@ref2]\]^. Although the symptoms of these two disorders can vary dramatically, acute agitation and aggression are relatively common among patients with either condition. The purpose of this review is to outline the diagnosis, clinical assessment, and treatment of hospitalized schizophrenia and bipolar disorder patients with acute agitation or aggression, and to present the latest evidence describing the use of atypical antipsychotics in these patient populations.

Several major English databases (MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials) were searched up to March 2016 using the following key words: ("schizophrenia" OR "bipolar disorder") AND ("agitation" OR "aggression" OR "hostility") AND ("antipsychotic" OR "atypical antipsychotic"). The abstracts of all records were scanned for relevance, and full-text of all potentially relevant articles was evaluated for inclusion. The reference lists of all full-text publications were searched for additional studies. Only English language articles were included.

2. Prevalence and correlates of agitation, aggression, violence and hostility in patients with bipolar disorder or schizophrenia {#sec1-2}
================================================================================================================================

 {#sec2-1}

### Agitation {#sec3-1}

Agitation, or "psychomotor agitation", is a poorly-defined psychomotor activity accompanying physical or mental unease. It often occurs in patients with psychoses, including schizophrenia, and in acutely exacerbated bipolar disorder ^\[[@ref3],[@ref4]\]^, often marking the beginning of a behavioral emergency, i.e., a situation with the potential to rapidly escalate. Thus, agitation can lead to, but is characterized separate from, physical aggression ^\[[@ref5]\]^. Agitation is characterized by the following hallmarks: motor restlessness, increased responsiveness to stimuli, irritability and excitement, excitement, restlessness, anxiety, psychic and motor tension, as well as excessive, inappropriate, and purposeless verbal and/or motor activity ^\[[@ref3]\]^.

### Aggression and violence {#sec3-2}

Aggression is a significant public health problem, and a number of studies have suggested that patients with schizophrenia and bipolar disorder have an increased risk of violent behavior compared with most other psychiatric patients ^\[[@ref6],[@ref7]\]^. There are two general subtypes of aggression: instrumental aggression, which is goal-directed and generally controlled, and reactive aggression, which involves an emotional reaction to a perceived threat or frustration, which is the most prevalent form ^\[[@ref8],[@ref9]\]^.

A number of studies have assessed the prevalence of aggression in patients with schizophrenia, and it is generally more common in the inpatient setting than in the general population. Zhou et al. performed a metaanalysis of 19 studies comprising 3941 hospitalized schizophrenia patients in China^\[[@ref10]\]^, and revealed that the prevalence of aggressive behavior was 15.3--53.2%, with a pooled prevalence of 35.4% (95% confidence interval \[CI\], 29.7--41.4%). Consistent with this, a systematic literature review of Chinese inpatients revealed a high prevalence of aggression in individuals with schizophrenia (mean, 28.0%; range, 9.1--49.6%) ^\[[@ref11]\]^. In contrast, the pooled prevalence of aggressive behavior reported from most Western countries is approximately 3--15% ^\[[@ref12]\]^. However, differences need to be interpreted with caution, since until 2012 there was no national Mental Health Law in China ^\[[@ref13]\]^ and \>80% of psychiatric patients were admitted involuntarily^\[[@ref14]\]^.

A recent systematic review and meta-analysis performed in non-hospitalized patients investigated the association between schizophrenia (and other psychoses) and violence ^\[[@ref15]\]^. In 20 studies reporting on a total of 18,423 patients there was a significant increase in violence in individuals with schizophrenia compared with the general population: 10% of patients with psychotic disorders including schizophrenia behaved aggressively, compared with only 2% of the general population (odds ratio \[OR\], 2.1; 95% CI, 1.7--2.7, and OR, 8.9; 95% CI, 5.4--14.7 with and without substance abuse as a comorbidity, respectively). In addition, the risk of committing homicide was 20-fold higher in patients with psychotic disorders ^\[[@ref15]\]^.

There are also clear links between bipolar disorder and aggression, even for patients in remission ^\[[@ref6],[@ref16]\]^. Corrigan and Watson assessed the prevalence of aggression in individuals with bipolar disorder and no psychiatric disorder using household interviews, and reported a lifetime prevalence of 12.2% and 1.9%, respectively; the corresponding numbers for "last year" aggression were 16.0% and 2.0%, respectively ^\[[@ref19]\]^. Furthermore, Látalová performed a review of studies published between 1966 and 2008, and indicated that according to the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) conducted in 2001--2002, the prevalence of aggression was 0.7% in control subjects compared with 25.3% in patients with bipolar I disorder; again, these effects were exacerbated by the presence of comorbidities ^\[[@ref20]\]^. Nevertheless, the authors cautioned that the true prevalence of aggression in individuals with bipolar disorder is difficult to ascertain because it is commonly only one of many items that contributes to scales or subscales.

Finally, potential predictors of aggression or violence in the psychotic or manic patient include the following: past aggressive or violent behavior, criminal history of violence, violent victimization or childhood sexual abuse, comorbid personality or conduct disorder, abuse of alcohol and illicit drugs, economic deprivation, severe irritability, delusional ideas (e.g. delusional jealousy), and hallucinations, including voices inciting or commanding violent acts ^\[[@ref21]\]^.

### Agitation and Hostility {#sec3-3}

Hostility is a behavioral trait as opposed to an independent acute state; it is defined as a hostile, threatening, or unfriendly attitude or state. Although the prevalence of these behaviors is generally not investigated individually, patients with both schizophrenia and bipolar disorder tend to exhibit more hostile behavior than control patients, and this is thought to contribute to their poor social functioning ^\[[@ref24]\]^.

### Assessment of acute agitation and aggression in bipolar disorder or schizophrenia {#sec3-4}

Several scales have been used in studies for the assessment of acute agitation and aggression in schizophrenia and bipolar disorder. These include the Positive and Negative Syndrome Scale (PANSS) ^\[[@ref25]\]^ excited component subscale (PANSS-EC), which consists of the following five items: excitement, hostility, tension, uncooperativeness, and poor impulse control. Furthermore, the Modified Overt Aggression Severity Scale (MOAS) ^\[[@ref26]\]^, and the Overt Agitation Severity Scale (OASS) ^\[[@ref27]\]^ have also been used. Another scale used for this purpose is the simple, single-item, 7-point Behavioral Activity Rating Scale (BARS)^\[[@ref28]\]^ that ranges from 7, "violent, requires restraint" to 1, "difficult or unable to rouse"

### Guidelines for the treatment of acute agitation and aggression in bipolar disorder or schizophrenia {#sec3-5}

Symptoms such as acute agitation and aggression require rapid interventions to prevent harm to the patient or their caregivers, other patients, staff members, or the general public. Therefore, a number of treatment guidelines have been published for patients with bipolar disorder or schizophrenia.

In general, treatment guidelines for agitation and aggression recommend using purposeful behavioral and environmental de-escalation strategies before using other, more restrictive or invasive strategies ^\[[@ref5],[@ref29],[@ref30]\]^. Further, guidelines recommend using pharmacologic interventions targeting the underlying disorder or the acute agitation or aggression to avoid the need for more coercive methods, such as seclusion or physical restraints that can lead to injuries to patients or restraining staff members ^\[[@ref31]\]^. Electroconvulsive treatment (ECT) is generally only recommended as treatment for the refractory underlying psychotic or mood disorder that has not responded to first line pharmacologic interventions, but not as treatment primarily targeting agitation or aggression acutely, as consent procedures are unlikely to be successful in such situations and as the alliance and future treatment adherence may be compromised by such invasive first-line treatment ^\[[@ref35]\]^.

For example, for patients with schizophrenia the American Psychiatric Association (APA) recommends the use of an antipsychotic, which should be determined based on the patient's previous experience with side effects, the degree of symptom response, and preferred route of administration, together with an adjunctive benzodiazepine to manage acute agitation, anxiety, and catatonia as needed (<http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf>). A beta-blocker or mood stabilizer could also be considered in individuals with persistent aggression (although the data for these types of treatments are much less firm). The suggested antipsychotics include short-acting intramuscular ziprasidone, olanzapine, or haloperidol, as well as oral olanzapine or risperidone. Similar to the APA, the schizophrenia Patient Outcomes Research Team (PORT) recommends that patients with acute agitation be treated using an oral or intramuscular (IM) atypical antipsychotic such as olanzapine, ziprasidone, or aripiprazole, either as a monotherapy or with an adjunctive fast-acting benzodiazepine ^\[[@ref36]\]^.

In patients with bipolar disorder and acute agitation or aggression, the APA recommends an antipsychotic together with lithium or valproate for a mixed manic episode, or any of these agents as a monotherapy for less severe episodes. A benzodiazepine may also be required to treat agitation. Alternative treatments could include the addition of carbamazepine or oxcarbazepine with or without an antipsychotic. Treatment-resistant patients could benefit from ECT (<http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf>).

In 2013, the Canadian Network for Mood and Anxiety Treatments (CANMAT) released the fourth edition of their recommendations for the management of patients with bipolar disorder ^[@ref37]^. Similar to the APA guidelines, lithium, valproate, and a number of atypical antipsychotics are recommended as first-line therapies for acute mania. Other recommended first-line options include adjunctive asenapine, as well as monotherapy with extended-release paliperidone, extended-release divalproex, and asenapine ^\[[@ref37]\]^.

In 2015, the second edition of Chinese guideline for schizophrenia recommended similar strategies as recommended in the APA guidelines for the treatment of acute agitation and aggression. After the necessary psychiatric assessment, the first-line therapies are intramuscular injection antipsychotic agents, such as ziprasidone or haloperidol, or oral atypical antipsychotics combined with a benzodiazepine. If first-line therapies do not work, then clozapine or an antipsychotic combined with a mood stabilizer are recommended. When second-line therapies fail, then modified ECT should be considered ^\[[@ref38]\]^.

Notably, although guidelines recommend the use of ECT only for treatment-resistant patients (<http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf>, ^\[[@ref38]\]^), in China modified ECT is not utilized infrequently as a fast-acting, first-line treatment strategy for agitated and aggressive patients with schizophrenia and bipolar disorder. A recently completed meta-analysis of 11 Chinese randomized controlled trials (RCTs) pooled data from five ECT monotherapy trials (n=340) and six trials that used ECT adjunctively with newly started antipsychotic treatment (n=408) and reported on the efficacy of modified ECT for agitation and aggression in schizophrenia. The results indicated that in the studies lasting on average 3.2(2.5) weeks (range, 1-8 weeks; median, 2 weeks), ECT monotherapy was superior to antipsychotic monotherapy regarding the PANSS total score as well as the PANSS-EC subscore ^\[[@ref42]\]^. However, ECT monotherapy was associated with significantly more headache and urinary incontinence than antipsychotic monotherapy. Similarly, ECT-antipsychotic co-initiation treatment was more efficacious than antipsychotic monotherapy regarding PANSS total score and the PANSS-EC subscore reduction, but was also associated with significantly more headache and memory impairment ^\[[@ref42]\]^.

2.2 Pharmacologic treatment of agitation and aggression in patients with schizophrenia and bipolar disorder {#sec2-2}
-----------------------------------------------------------------------------------------------------------

Based on the current treatment guidelines, one central the aim of this review was to assess the current use of antipsychotics for the treatment of schizophrenia and bipolar disorder patients with acute agitation and aggression. Relevant studies were identified using the following search terms conducting an electronic search in PubMed on February 1^st^, 2016: (agitation OR agitated OR aggression OR aggressive OR hostile OR hostility OR violent OR violence) AND (schizophr\* OR psychosis OR psychot\* OR psychos\* OR mania OR manic OR bipolar) AND (antipsychotic\* OR neuroleptic). The studies included were limited to English language, human studies, and to mostly placebo-controlled RCTs or meta-analyses. Because several excellent reviews are available that discuss the history of these agents in detail ^\[[@ref43]\]^ we focused mostly on recent developments in the field.

2.3 Antipsychotics {#sec2-3}
------------------

One of the main treatments for acute agitation and aggression in patients with schizophrenia and bipolar disorder assessed in placebo-controlled RCTs are antipsychotics. They can be divided into two classes: typical (or first-generation), and atypical (or second-generation) drugs. Both typical and atypical antipsychotics are believed to work by reducing dopamine receptor signaling in the brain. However, atypical antipsychotics can also inhibit serotonin (5- HT, and particularly 5-HT~2A~) signaling, as well as to variable degrees adrenergic, cholinergic, and histamine receptors. One of the main differences between typical and atypical antipsychotics is their associated side-effects ^\[[@ref48]\]^. Generally, atypical antipsychotics are associated with a significantly reduced risk of extrapyramidal symptoms (EPS), such as akathisia, Parkinsonism, and dystonia^\[[@ref49]\]^. However, some atypical agents have a higher risk of causing significant weight gain and metabolic side effects ^\[[@ref50]\]^.

2.4 Atypical antipsychotics {#sec2-4}
---------------------------

### Aripiprazole {#sec3-6}

Aripiprazole is an atypical antipsychotic with an indication for the treatment of acutely agitated patients with bipolar disorder or schizophrenia in its IM formulation ^\[[@ref51]\]^. It is thought to function at least in part by exhibiting partial agonist activity at 5-HT~1A~ and dopamine D~2~ receptors, as well as antagonist activity at 5-HT~2A~ receptors ^\[[@ref52]\]^. The mean half-life of IM and oral aripiprazole is 75 hours, and peak concentrations are observed within 1--3 hours and 3--5 hours, respectively ^\[[@ref52]\]^.

A post-hoc analysis of pooled data from four placebo-controlled RCTs was performed to assess the effectiveness of 10, 15, 20, or 30 mg/day oral aripiprazole to reduce agitation in 1187 schizophrenia patients with higher and lower levels of agitation ^\[[@ref53]\]^. Comparison of clinical global impression -- improvement (CGI-I), PANSS total, and PANSS-EC scores between aripiprazole and placebo-treated patients revealed that aripiprazole reduced agitation significantly, particularly in those with higher levels of pre-treatment agitation. Comparable observations were made in a post-hoc analysis of two 3-week randomized placebo-controlled trials comparing the efficacy of oral aripiprazole and placebo in bipolar I disorder patients with acute mania ^\[[@ref54],[@ref55]\]^.

Several studies compared the effects of IM aripiprazole with the typical antipsychotic haloperidol in patients with schizophrenia-spectrum disorders ^\[[@ref56]\]^. In a randomized, double-blind, placebo-controlled trial, 448 hospitalized patients with schizoaffective disorder or schizophrenia were treated with placebo, 6.5 mg IM haloperidol, or 9.75 mg IM aripiprazole for a mean 1.92, 1.43, and 1.54 doses, respectively, and the mean change in PANSS-EC score between baseline and 2 hours was assessed. Aripiprazole IM improved acute agitation significantly compared with placebo, but there was no significant difference in the efficacy of IM aripiprazole and IM haloperidol. Although IM aripiprazole was associated with adverse events, such as nausea, insomnia, dizziness, and headache, EPS were more common in the IM haloperidol vs. IM aripiprazole group ^\[[@ref58]\]^. The same authors compared the efficacy of transitioning from IM to oral aripiprazole or haloperidol over a 24-hour period in a sub-population analysis of a randomized, double-blind study in 325 schizophrenia patients with aggression. The patients received 1--3 IM doses of 9.75 mg aripiprazole, 6.5 mg haloperidol, or placebo at hours 0, 2, and 4 hours (as necessary), before transitioning to oral therapy. Although the efficacy of both treatment regimens was similar, as determined using PANSS-EC scores, IM haloperidol was associated with significantly more EPS (0%, 1.6%, and 16.5% with IM aripiprazole, placebo, and IM haloperidol, respectively) ^\[[@ref56]\]^. In a multicenter, randomized, double-blind, placebo-controlled study, 357 patients with schizophrenia or schizophreniform disorders were treated with 1, 5.25, 9.75, or 15 mg IM aripiprazole, 6.5 mg IM haloperidol or placebo, and agitation was assessed using the change in PANSS-EC score between baseline and 2 hours after dosing. Agitation was reduced by 9.75 mg IM aripiprazole compared with placebo within 45 min, whereas IM haloperidol did not separate from placebo until 105 minutes ^\[[@ref57]\]^.

Similar observations as in schizophrenia were made with IM aripiprazole in patients with bipolar disorder. For example, Zimbroff et al. performed a multicenter randomized, double-blind study in 301 patients with bipolar I disorder experiencing manic or mixed episodes of acute agitation ^\[[@ref54]\]^. Patients were treated with 2 mg IM lorazepam, placebo, 9.75 mg IM aripiprazole, or 15 mg IM aripiprazole, and the symptoms of agitation were assessed by comparing PANSS-EC scores at baseline and 2 hours after treatment. Both doses of aripiprazole and lorazepam reduced agitation significantly, but there were no differences among treatment groups. The authors noted that the safety profile of IM aripiprazole was similar to that of the oral formulation, and that the low incidence of over-sedation in the patients receiving 9.75 mg/dose was encouraging ^\[[@ref54]\]^.

### Asenapine {#sec3-7}

Asenapine is a tetracyclic atypical antipsychotic drug that received approval from the United States Food and Drug Administration (FDA) in 2009 for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. Unlike other atypical antipsychotics, asenapine is administered sublingually, since the bioavailability after oral administration is only 2% ^\[[@ref59]\]^. It has no IM formulation and its sublingual half-life is approximately 24 hours; maximum plasma levels are reached in 30--90 minutes. Similar to many atypical antipsychotics, asenapine has high affinity for a number of receptors in the brain. Specifically, it exhibits antagonist activity at D~2~, D~3~, and D~4~ dopaminergic receptors, 5-HT~2A~, 5-HT~2B~, 5-HT~2C~, 5-HT~6~, and 5-HT~7~ serotonin receptors, and α1A and α2 adrenergic receptors; it has a particularly high affinity for 5-HT~2A~ ^\[[@ref60]\]^.

Asenapine appears to reduce agitation effectively in patients with a variety of different diagnoses ^\[[@ref61]\]^. However, we were unable to identify any studies meeting our search criteria that specifically assessed the effects of asenapine in schizophrenia or bipolar disorder patients with acute agitation and aggression. Nevertheless, a number of studies have assessed the efficacy of asenapine in patients with schizophrenia and bipolar disorder. Overall, the current data suggest that asenapine is effective for the long- and short-term management of these patients, and that it exhibits comparable efficacy to many other atypical antipsychotics ^\[[@ref62]\]^. Few adverse events have been reported with asenapine: studies suggest that it has a relatively neutral metabolic profile, and also a relatively low propensity to elevate prolactin levels and cause weight gain ^\[[@ref62]\]^.

### Brexpiprazole {#sec3-8}

Brexpiprazole is a new atypical antipsychotic that received approval for the treatment of bipolar disorder, schizophrenia and major depressive disorder (as an adjunct with antidepressants) from the FDA in July 2015. Brexpiprazole is thought to exert its effects by acting both as a partial agonist of serotonin 5-HT~1A~ and dopamine D~2~ receptors and an antagonist of serotonin 5-HT~2A~ and noradrenaline α~1B~ and α~2C~ receptors, all with similar potency. The intrinsic activity of brexpiprazole at D~2~ receptors is lower than that of aripiprazole. It is currently only available as an oral formulation; it has a mean half-life of 2--3 days, and peak plasma concentrations are observed after 4 hours ^\[[@ref68]\]^. In a pooled analysis of two large phase 3 trials, both the 2 mg and 4 mg doses of brexpiprazole improved the PANSS-EC score significantly more than placebo ^\[[@ref69]\]^.

### Cariprazine {#sec3-9}

Cariprazine is a new atypical antipsychotic drug that received approval for the treatment of bipolar disorder and schizophrenia from the FDA in September 2015. Unlike most antipsychotics, the main mechanism of action of cariprazine is thought to be partial agonistic effects at both the D~2~ and D~3~ receptors ^\[[@ref70]\]^. The functional intrinsic activity of cariprazine at D~2~ receptors may be somewhat similar to that of aripiprazole. It is currently only available as an oral formulation and has a mean half-life of 2--5 days ^\[[@ref71]\]^, and peak plasma concentrations are observed after 1.1--3.6 hours ^\[[@ref72]\]^.

In a post-hoc analysis of three studies, Citrome et al. reported that oral cariprazine reduced the PANSS hostility score significantly in patients with schizophrenia compared with placebo ^\[[@ref73]\]^. Similarly, Vieta et al. performed a post-hoc analysis of pooled data from three phase II and III clinical trials ^\[[@ref74]\]^ to assess the effects of 3--12 mg/day oral cariprazine on the symptoms of 1037 patients with bipolar mania in an intent-to-treat population^\[[@ref77]\]^. The endpoints of the analysis were change in Young mania rating scale (YMRS) score from baseline to the end of the study. Cariprazine improved all 11 items of the YMRS significantly compared with control, and cariprazine-treated patients experienced no or only very mild symptoms after treatment, although akathisia and EPS were observed.

### Clozapine {#sec3-10}

Clozapine is an atypical antipsychotic that exerts its effects by antagonizing dopamine D~2~ and serotonin 5-HT~2A~ as well as histamine H~1~ receptors, although multiple other receptor systems are also involved with unclear relevance for the enhanced clinical efficacy of clozapine ^\[[@ref52]\]^. The half-life and peak plasma concentration of oral clozapine were reported to be 9.1--17.4 h and 1.1--3.6 h, respectively ^\[[@ref78]\]^. Clozapine has not been studied as an IM formulation. In a mirror-image study, 137 aggressive patients with schizophrenia or schizoaffective disorder were treated with 200--625 mg/day oral clozapine or an alternative treatment, and the frequency of aggression was assessed by counting the number of times seclusion or restraints had to be used to calm the patient. Over the 12-month duration of the study, oral clozapine reduced the use of both restraints (0.34 (0.47) vs. 0.08 (0.23), *Z* = --2.27, *p*=0.032) and seclusion (0.44 (0.46) vs. 0.16 (0.32), *Z* = --3.91, *p*\<0.001) significantly compared with the same patients in the pre-clozapine period ^\[[@ref79]\]^. The authors did not comment on any adverse events that were observed.

A number of studies have also been performed to compare oral clozapine with other oral antipsychotics (e.g., \[[@ref80], [@ref81]\]). For example, Volavka et al. ^\[[@ref80]\]^ performed a randomized double-blind trial that consisted of a 6-week escalation and fixed-dose period and a 6-week variable dose period. The 157 hospitalized treatment-resistant patients with schizophrenia or schizoaffective disorder received oral doses of clozapine, olanzapine, or haloperidol that were escalated to the target levels (500, 20, and 20 mg/day, respectively), and then fixed. In the second period of the study, the dose varied within a pre-defined range (clozapine, 200--800 g/day; olanzapine, 10--35 mg/day; haloperidol, 10--30 mg/day; risperidone, 4--16 mg/day) as needed. The MOAS was used to rate aggressive symptoms. Clozapine was the most effective drug in patients with the strongest symptoms of aggression, whereas olanzapine and risperidone were more effective when symptoms were milder ^\[[@ref80]\]^. Haloperidol was the least effective agent when all drugs were used at the same effective dose. Although the authors reported measuring adverse events, they did not comment on the incidence of any specific side effects. Similar observations were made in a subsequent randomized, double-blind, parallel-group trial of 110 inpatients with schizophrenia or schizoaffective disorder, where oral clozapine was more effective than oral olanzapine and haloperidol at reducing the MOAS score. However, there were no differences in PANSS total or subscale scores between groups ^\[[@ref81]\]^.

### Olanzapine {#sec3-11}

Olanzapine has been used for the treatment of both bipolar disorder and schizophrenia patients with acute agitation for a number of years. It functions in part by antagonizing 5-HT~1A~, 5-HT~3~, 5-HT~6~, and 5-HT~7~ receptors, as well as functioning as an inverse agonist at 5-HT~2B~ and 5-HT~2C~ receptors ^\[[@ref82]\]^. The half-life of oral and IM olanzapine is 30--38 hours and 34--34 hours, respectively, with peak plasma concentrations observed after 3--6 hours and 15--30 minutes, respectively ^\[[@ref83]\]^.

The multicenter, randomized active-controlled, parallel-group open-label European First-Episode Schizophrenia Trial (EUFEST) of orally administered antipsychotics assessed the ability of 5--20 mg/day olanzapine and four other antipsychotics (1--4 mg/day haloperidol, 200--800 mg/day amisulpride, 40--160 mg/day ziprasidone, and 200--750 mg/day quetiapine) to reduce hostility in 498 patients with first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder ^\[[@ref84],[@ref85]\]^. Analysis of PANSS-EC scores demonstrated that olanzapine was significantly superior to haloperidol, quetiapine, and amisulpride at reducing hostility after 1 and 3 months. In contrast, a prospective, randomized, rater-blinded, controlled design within a naturalistic treatment regimen revealed that there were no differences in the effectiveness of 10 mg haloperidol, 15 mg olanzapine, and 2 mg risperidone (all oral) in the rapid tranquilization of severely agitated patients with schizophrenia-related disorders within 2 hours, as determined using PANSS psychotic agitation subscale (PANSS-PAC) scores ^\[[@ref86]\]^. No significant motor-related side effects were reported, but the authors did not comment on the presence of any other adverse events.

A randomized controlled trial performed in 90 hospitalized Japanese patients with acute psychotic aggression compared the effectiveness of IM olanzapine (10 mg) with placebo. Patients were followed for 24 hours after dosing, and drug efficacy was assessed using the mean change in PANSS-EC score ^\[[@ref87]\]^. Data revealed that olanzapine improved the PANSS-ES score significantly compared with placebo, and that it was well-tolerated ^\[[@ref87]\]^. Importantly, other studies have shown that only a single dose of olanzapine is often required to control symptoms of acute agitation in patients with bipolar disorder or schizophrenia ^\[[@ref83]\]^.

Several other studies have been performed to compare the efficacy of IM olanzapine with other agents (81, 88). For example, Breier et al. compared the effects of 1--3 doses of IM olanzapine (2.5, 5.0, 7.5, or 10.0 mg), haloperidol (7.5 mg), and placebo in 270 hospitalized schizophrenia patients with acute agitation, and then measured PANSS-EC score at baseline and 2-hours after treatment. Both antipsychotics reduced PANSS-EC score significantly and there were no efficacy differences between olanzapine and haloperidol; the effects of olanzapine were dose-dependent ^\[[@ref88]\]^. The main adverse event associated with olanzapine was hypotension, which occurred at a similar rate in haloperidol-treated patients. Dystonia was observed in 5% of individuals treated with haloperidol, but none of those who received olanzapine.

In a prospective, observational study, IM olanzapine was compared with IM formulations of the typical antipsychotics haloperidol and zuclopenthixol in 2011 schizophrenia or acute mania inpatients. Individuals treated first with IM olanzapine exhibited significantly greater decreases in PANSS-EC and CGI -- severity (CGI-S) scores after 24 hours, 72 hours, and 7 days ^\[[@ref89]\]^, but there was no difference after 2 hours (81). Patients treated with IM olanzapine also experienced fewer EPS than those treated with IM typical antipsychotics. Similar observations were made in a subsequent randomized, double-blind, parallel-group study, where olanzapine was more effective than haloperidol at reducing the MOAS score in 100 inpatients with schizoaffective disorder. However, there was no difference in total or subscale PANSS scores between groups ^\[[@ref81]\]^. Unfortunately, the authors of this study did not describe whether the drugs were administered IM or orally.

### Quetiapine {#sec3-12}

Quetiapine is an atypical antipsychotic that was first approved by the FDA for schizophrenia in 1997. It only exists in oral formulation and has a half-life of approximately 7 hours, and peak plasma concentrations are observed around 90 minutes. It functions by inhibiting a number of receptors in the brain, including α1 and α2 adrenergic, histamine H1, D~1~ and D~2~ dopamine, and 5-HT~1A~ and 5-HT~2~ serotonin receptors ([www.rxlist.com](www.rxlist.com)).

Data from 257 acutely agitated patients with schizophrenia in a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial were re-analyzed to compare the ability of oral quetiapine and haloperidol to reduce the symptoms of agitation. The patients received placebo, 12 mg/day oral haloperidol, or 75, 150, 300, 600, or 750 mg/day oral quetiapine for 6 weeks; doses were titrated over the first 2 weeks, and were then fixed. Patient agitation was determined by measuring Brief Psychiatric Rating Scale (BPRS) scores at baseline and at weeks 1--6 ^\[[@ref90]\]^. The resulting analysis revealed that quetiapine reduced BPRS scores significantly compared with both placebo and haloperidol. As discussed above, quetiapine also reduced hostility in patients with first-episode schizophrenia in the EUFEST trial, although olanzapine was more effective ^\[[@ref84]\]^.

To assess the efficacy of quetiapine in bipolar disorder patients with acute mania, McIntyre et al. analyzed the combined data from four randomized, double-blind, placebo-controlled trials assessing oral quetiapine alone or in combination with lithium or divalproex ^\[[@ref91]\]^. The main outcomes of interest were changes in YMRS and PANSS scores. Quetiapine improved acute mania significantly, including aggression (as determined using PANSS-supplemental aggression risk \[SAR\] scores), either when given as monotherapy or combination therapy.

### Ziprasidone {#sec3-13}

Ziprasidone is an atypical antipsychotic agent that was approved by the FDA in 2001 for schizophrenia, and in 2004 for bipolar disorder ^\[[@ref92]\]^. It was first used orally, and subsequently intramuscularly (IM) for the treatment of agitated psychosis ^\[[@ref92]\]^. It functions by exhibiting agonist activity at 5-HT~1A~ receptors, inverse agonist activity at 5-HT~2A~ receptors, and antagonist activity at 5-HT~1D~ and 5-HT~2C~ receptors ^\[[@ref92],[@ref93]\]^. A number of studies have confirmed that ziprasidone is a safe and effective treatment for agitation in patients with schizophrenia. The half-life of ziprasidone is 2.2--3.4 and 3.8 hours when given IM and orally, respectively, with peak plasma concentrations observed in 30--45 minutes and 8 hours, respectively^\[[@ref83]\]^. The recommended dose of ziprasidone is 10--20 mg IM, up to 40 mg daily IM, and 80--160 mg orally given in divided doses ^\[[@ref83]\]^.

One of the first studies assessing the efficacy of IM ziprasidone compared doses of 2 and 10 mg in 117 acutely agitated psychotic patients. The results of the 24-hour, fixed-dose, double blind study revealed that 10 mg ziprasidone reduced agitation rapidly, within 2 hours of the first dose, in more than half of the patients ^\[[@ref94]\]^. There were no cases of dystonia, but one patient that received the 10 mg dose experienced akathisia. In a similar study, Daniel et al. assessed the efficacy of 2 and 20 mg IM ziprasidone for the shortterm, acute management of 79 acutely agitated patients with psychosis in a prospective, randomized, double-blind study ^\[[@ref95]\]^. The 20 mg dose reduced BARS scores significantly compared with 2 mg within 30 min of dosing. The improvements increased until 2 hours, and were maintained until at least 4 hours after dosing. Both doses were well-tolerated and reduced the symptoms significantly, and no cases of excessive sedation, EPS, akathisia, dystonia, or respiratory depression were reported.

Several large Chinese studies compared the efficacy of ziprasidone with other treatments for acute agitation and aggression. In a randomized, rater-blinded, open-label study, 376 Chinese patients with schizophrenia were treated with IM ziprasidone (10--20 mg/dose and a maximum of 40 mg/day) or haloperidol (5 mg every 4--8 hours and a maximum of 20 mg/day) for 6 weeks, and hostility was assessed using BPRS scores. Ziprasidone exhibited a favorable tolerability and a numerically improved efficacy profile compared with haloperidol ^\[[@ref96]\]^. Similar observations were made in a randomized, rater-blinded, open-label study of patients with schizophrenia in which 572 patients were treated with sequential IM and oral ziprasidone or haloperidol, and the BPRS was used to assess hostility over a 6-week period ^\[[@ref97]\]^. The results revealed that ziprasidone exhibited potent anti-hostility effects that were statistically superior to haloperidol.

Similar to most atypical antipsychotics, ziprasidone is associated with a low frequency of EPS. The common side effects of ziprasidone include akathisia, dyspepsia, constipation, nausea, dizziness, abdominal pain, and somnolence ^\[[@ref98],[@ref99]\]^. Other side effects include prolonging the QTc interval, although the increase of the IM formulation might not be more than that caused by other agents, such as IM haloperidol ^\[[@ref100],[@ref101]\]^. Moreover, in a very large 1-year study of over 18,000 patients randomized to oral ziprasidone or oral olanzapine, no differences in all-cause mortality or cardiac-related complications were observed ^\[[@ref102]\]^. Importantly, ziprasidone exhibits favorable tolerability profiles compared with some other atypical antipsychotics, particularly because it is generally associated with only minimal weight gain and has a favorable metabolic profile (glycemic control, cholesterol, and triglycerides) ^\[[@ref103]\]^.

3. Conclusions {#sec1-3}
==============

The successful development and increased characterization of IM atypical antipsychotics, together with the introduction and FDA-approval of several novel agents, such as asenapine, brexpiprazole, and cariprazine that are currently only available as oral formulations, has increased the treatment options available for schizophrenia and bipolar disorder patients with frequently observed acute agitation and aggression.

In particular, the availability of several atypical antipsychotics as short-acting IM formulations (aripiprazole, olanzapine, ziprasidone) allow clinicians to initiate acute medications targeting acute agitation and aggression that can be continued safely as oral medications in patients requiring and responding to the acute short-acting IM treatment.

When non-pharmacologic de-escalation strategies fail, the early, appropriate use of IM antipsychotics can be instrumental to avoid further escalation to violence and dangerous situations. IM antipsychotics with or without adjunctive IM benzodiazepine use can help provide rapid and effective symptom relief, aiming to calm and not over-sedate the patient in order to allow a clinical history to be obtained. Moreover, IM antipsychotic use can help avert the use of coercive methods, such as seclusion, restraints, or even acute modified ECT. This approach can avoid compromising the development of a sufficient therapeutic alliance, which is crucial for the ongoing evaluation of the cause of agitation and aggression, and also subsequently increases the chances of treatment adherence during the maintenance treatment phase, which is highly important for treatment success ^\[[@ref104]\]^. It is hoped that the treatment armamentarium will be enriched by additional short-acting IM antipsychotic management options in the future.
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